First‐Line Lorlatinib in Striatin–Anaplastic Lymphoma Kinase‐Positive Lung Adenocarcinoma: A Case Report and Literature Review

Masaru Maebeya, Shinobu Tamura, Takeshi Shono, Takanobu Hoso, Hitomi Tatsuta · 2026

Read First‐Line Lorlatinib in Striatin–Anaplastic Lymphoma Kinase‐Positive Lung Adenocarcinoma: A Case Report and Literature Review by Masaru Maebeya, Shinobu Tamura, Takeshi Shono, Takanobu Hoso, Hitomi Tatsuta (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13541762.txt.

Description

Masaru Maebeya and co-authors report a lung cancer case with a rare gene fusion in a 2026 paper. The patient, a 45-year-old man, had lung adenocarcinoma driven by a striatin-ALK fusion, a variant so rare that the best first drug was unclear.

His cancer had already spread to the brain, which doctors treated with focused radiation. He then started lorlatinib, a drug built for ALK-driven tumors, as his first medicine. Nerve and mood side effects forced the dose down in steps, yet the cancer shrank and stayed controlled in body and brain for over a year. The case supports lorlatinib as a first choice for this rare subtype.

Catalog record

CREATORMasaru Maebeya, Shinobu Tamura, Takeshi Shono, Takanobu Hoso, Hitomi Tatsuta
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE18 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13541762

Browse the full library · About the Tower of Babel